$1.39
+0.09
(+6.92%)▲
6.47%
Downside
Day's Volatility :8.45%
Upside
2.11%
69.78%
Downside
52 Weeks Volatility :79.51%
Upside
32.2%
Period | Adaptimmune Therapeutics Plc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 20.93% | 6.5% | 0.0% |
6 Months | 78.08% | 7.1% | 0.0% |
1 Year | 39.78% | 9.8% | 0.0% |
3 Years | -62.96% | 14.2% | -20.2% |
Market Capitalization | 325.8M |
Book Value | $0.1 |
Earnings Per Share (EPS) | -0.73 |
PEG Ratio | 0.11 |
Wall Street Target Price | 2.08 |
Profit Margin | 0.0% |
Operating Margin TTM | -867.58% |
Return On Assets TTM | -44.57% |
Return On Equity TTM | -301.91% |
Revenue TTM | 18.4M |
Revenue Per Share TTM | 0.08 |
Quarterly Revenue Growth YOY | -88.1% |
Gross Profit TTM | -100.6M |
EBITDA | -183.9M |
Diluted Eps TTM | -0.73 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.48 |
EPS Estimate Next Year | -0.45 |
EPS Estimate Current Quarter | -0.1 |
EPS Estimate Next Quarter | -0.06 |
What analysts predicted
Upside of 49.64%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 59.5M | ↑ 57.28% |
Net Income | -95.5M | ↑ 36.18% |
Net Profit Margin | -160.51% | ↑ 24.88% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.1M | ↓ 98.11% |
Net Income | -137.2M | ↑ 43.61% |
Net Profit Margin | -12.2K% | ↓ 12064.53% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 4.0M | ↑ 252.76% |
Net Income | -130.1M | ↓ 5.16% |
Net Profit Margin | -3.3K% | ↑ 8938.23% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 6.1M | ↑ 55.36% |
Net Income | -158.1M | ↑ 21.52% |
Net Profit Margin | -2.6K% | ↑ 715.82% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 27.1M | ↑ 341.5% |
Net Income | -165.5M | ↑ 4.66% |
Net Profit Margin | -609.46% | ↑ 1961.53% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 60.5M | ↑ 122.91% |
Net Income | -114.3M | ↓ 30.91% |
Net Profit Margin | -188.9% | ↑ 420.56% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.0M | ↑ 57.39% |
Net Income | -29.3M | ↓ 29.38% |
Net Profit Margin | -265.23% | ↑ 325.91% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 47.6M | ↑ 331.64% |
Net Income | 1.0M | ↓ 103.54% |
Net Profit Margin | 2.18% | ↑ 267.41% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.1M | ↓ 89.22% |
Net Income | -21.4M | ↓ 2164.58% |
Net Profit Margin | -416.94% | ↓ 419.12% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.3M | ↑ 42.67% |
Net Income | -45.6M | ↑ 113.2% |
Net Profit Margin | -623.05% | ↓ 206.11% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 233.0K | ↓ 96.82% |
Net Income | -48.3M | ↑ 5.99% |
Net Profit Margin | -20.7K% | ↓ 20120.28% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 5.7M | ↑ 2336.82% |
Net Income | -48.5M | ↑ 0.35% |
Net Profit Margin | -854.23% | ↑ 19889.1% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 276.7M | ↓ 1.57% |
Total Liabilities | 29.9M | ↓ 61.81% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 181.5M | ↓ 34.4% |
Total Liabilities | 57.9M | ↑ 93.98% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 451.1M | ↑ 148.5% |
Total Liabilities | 109.9M | ↑ 89.82% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 469.5M | ↑ 4.08% |
Total Liabilities | 263.6M | ↑ 139.81% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 328.9M | ↓ 29.95% |
Total Liabilities | 247.0M | ↓ 6.28% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 282.6M | ↓ 14.08% |
Total Liabilities | 243.1M | ↓ 1.59% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 328.9M | ↓ 0.99% |
Total Liabilities | 247.0M | ↑ 12.87% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 288.1M | ↓ 12.42% |
Total Liabilities | 204.2M | ↓ 17.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 343.0M | ↑ 19.06% |
Total Liabilities | 216.3M | ↑ 5.94% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 296.6M | ↓ 13.51% |
Total Liabilities | 208.5M | ↓ 3.62% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 282.6M | ↓ 4.73% |
Total Liabilities | 243.1M | ↑ 16.59% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 258.0M | ↓ 8.71% |
Total Liabilities | 233.6M | ↓ 3.89% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -104.4M | ↑ 92.19% |
Investing Cash Flow | -17.5M | ↓ 86.15% |
Financing Cash Flow | 102.7M | ↓ 0.85% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -112.5M | ↑ 7.78% |
Investing Cash Flow | 94.9M | ↓ 643.88% |
Financing Cash Flow | 366.0K | ↓ 99.64% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -53.6M | ↓ 52.37% |
Investing Cash Flow | -278.9M | ↓ 393.77% |
Financing Cash Flow | 340.1M | ↑ 92810.11% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.7M | ↓ 120.02% |
Investing Cash Flow | 75.8M | ↓ 127.18% |
Financing Cash Flow | 3.3M | ↓ 99.03% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -141.8M | ↓ 1421.36% |
Investing Cash Flow | 89.1M | ↑ 17.59% |
Financing Cash Flow | 12.9M | ↑ 291.33% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.0M | ↓ 104.24% |
Investing Cash Flow | 21.0M | ↓ 27.38% |
Financing Cash Flow | 1.4M | ↓ 3.37% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -37.3M | ↓ 1925.81% |
Investing Cash Flow | 2.7M | ↓ 87.14% |
Financing Cash Flow | 196.0K | ↓ 86.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -43.8M | ↑ 17.38% |
Investing Cash Flow | 2.7M | ↑ 0.0% |
Financing Cash Flow | 14.0K | ↓ 92.86% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -45.2M | ↑ 3.19% |
Investing Cash Flow | 57.3M | ↑ 2027.17% |
Financing Cash Flow | 596.0K | ↑ 4157.14% |
Sell
Neutral
Buy
Adaptimmune Therapeutics Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Adaptimmune Therapeutics Plc | 56.34% | 78.08% | 39.78% | -62.96% | -59.12% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Adaptimmune Therapeutics Plc | NA | NA | 0.11 | -0.48 | -3.02 | -0.45 | NA | 0.1 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Adaptimmune Therapeutics Plc | Buy | $325.8M | -59.12% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Adaptimmune Therapeutics Plc
Revenue is up for the last 2 quarters, 233.00K → 5.67M (in $), with an average increase of 95.9% per quarter
Netprofit is down for the last 5 quarters, 1.03M → -48.50M (in $), with an average decrease of 571.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 21.8%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 249.5%
Matrix Capital Management Company, LLC
EcoR1 Capital, LLC
NEA Management Company, LLC
Baillie Gifford & Co Limited.
Baker Bros Advisors LP
Long Focus Capital Management, LLC
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Organization | Adaptimmune Therapeutics Plc |
Employees | 449 |
CEO | Mr. Adrian G. Rawcliffe |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.39
+6.92%
Keyarch Acquisition Corp
$1.39
+6.92%
Connexa Sports Technologies Inc
$1.39
+6.92%
Us Value Etf
$1.39
+6.92%
First Wave Biopharma Inc
$1.39
+6.92%
Global X Msci Next Emerging
$1.39
+6.92%
Fat Projects Acquisition Corp
$1.39
+6.92%
Capital Link Global Fintech
$1.39
+6.92%
Applied Uv Inc
$1.39
+6.92%